Medpace FY2026 EPS Estimate Decreased by Leerink Partnrs

Key Points

• Analysts at Leerink Partners have reduced their FY2026 EPS estimate for Medpace to $15.67, down from the previous estimate of $15.78, while the consensus for the current year's earnings is $12.29 per share.
• Shares of Medpace recently opened at $518.69 and have experienced a 2.3% decline, with a market cap of $14.57 billion.
• The current consensus rating on Medpace’s stock is a "Hold" with a price target averaging $422.27, with 3 analysts rating it as a Buy, 12 as Hold, and 3 as Sell.

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Research analysts at Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for Medpace in a research report issued on Wednesday, October 8th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $15.67 per share for the year, down from their previous forecast of $15.78. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's FY2027 earnings at $17.63 EPS and FY2028 earnings at $19.99 EPS.

Other equities research analysts have also recently issued reports about the company. TD Cowen reiterated a "sell" rating and set a $366.00 price target (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Rothschild Redb cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Zacks Research cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Robert W. Baird upped their price objective on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Truist Financial increased their price target on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $422.27.

Medpace Stock Down 2.3%

Shares of MEDP opened at $518.69 on Friday. The business's 50-day moving average price is $481.76 and its 200-day moving average price is $373.31. Medpace has a twelve month low of $250.05 and a twelve month high of $547.15. The stock has a market cap of $14.57 billion, a PE ratio of 38.56, a P/E/G ratio of 3.34 and a beta of 1.40.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. During the same period in the prior year, the business posted $2.75 earnings per share. The company's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS.

Insider Activity

In other news, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This trade represents a 22.48% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

Institutional Trading of Medpace

Institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the period. Brooklyn Investment Group lifted its stake in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. lifted its stake in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after acquiring an additional 35 shares during the period. Employees Retirement System of Texas purchased a new stake in Medpace in the second quarter worth $36,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Medpace in the first quarter worth $60,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.